Remacemide
Title: Remacemide
CAS Registry Number: 128298-28-2
CAS Name: 2-Amino-N-(1-methyl-1,2-diphenylethyl)acetamide
Molecular Formula: C17H20N2O
Molecular Weight: 268.35
Percent Composition: C 76.09%, H 7.51%, N 10.44%, O 5.96%
Literature References: NMDA receptor antagonist. Prepn: R. C. Griffith, J. J. Napier, EP 279937 (1988 to Pennwalt); see also: eidem, US 5331007 (1994 to Fisons). Pharmacology, metabolism and pharmacokinetics: K. T. Muir, G. C. Palmer, Epilepsy Res. Suppl. 3, 147 (1991). HPLC determn in plasma: J. W. Flynn, J. E. O'Brien, J. Chromatogr. 583, 91 (1992). Mechanism of action study: S. Subramaniam et al., J. Pharmacol. Exp. Ther. 276, 161 (1996). Neuroprotective properties: G. C. Palmer et al., Ann. N.Y. Acad. Sci. 765, 236 (1995). Clinical evaluation in neuroprotection during cardiac surgery: J. E. Arrowsmith et al., Stroke 29, 2357 (1998); in Parkinson's disease: Parkinson Study Group, Neurology 56, 455 (2001). Review of mechanism of action and clinical applications: S. C. Schachter, D. Tarsy, Expert Opin. Invest. Drugs 9, 871-883 (2000).
 
Derivative Type: Hydrochloride
CAS Registry Number: 111686-79-4
Manufacturers' Codes: FPL-12924AA; PR-934-423A
Molecular Formula: C17H20N2O.HCl
Molecular Weight: 304.81
Percent Composition: C 66.99%, H 6.94%, N 9.19%, O 5.25%, Cl 11.63%
Properties: Crystals from isopropanol + methanol, mp 253-254°. Soly (g/l): water 40; normal saline 22; dilute HCl 26; ethanol 24. LD50 (calculated as base) in rats (mg/kg): ~50 i.v., ~900 orally (Muir, Palmer).
Melting point: mp 253-254°
Toxicity data: LD50 (calculated as base) in rats (mg/kg): ~50 i.v., ~900 orally (Muir, Palmer)
 
Therap-Cat: Neuroprotective.
Keywords: Neuroprotective; NMDA Receptor Antagonist.

Others monographs:
Potassium BisulfideFurfuralAripiprazole1,1-Diphenyl-2-picrylhydrazyl (Free Radical)
TerbutalineLead Chromate(VI) OxideParaformaldehydePilocarpus
Potassium Tetroxalaten-Nonyl AcetateSolanoneCupric p-Phenolsulfonate
Mercuric ArsenateNickel Ammonium SulfateAtracurium BesylateLeptandra
©2016 DrugLead US FDA&EMEA